Fundraising Fox

Denali Therapeutics

NASDAQ: DNLI

San Francisco, US · Incorporated in Delaware · 5 known investors

denalitherapeutics.com ↗

Denali Therapeutics develops therapeutics for neurodegenerative diseases. The company focuses on discovering and developing novel drug candidates targeting specific neurological conditions.

BiotechHealthtechMedical Devices

Founders & leadership

CH
Carole HoExecutive Officer
VL
Vicki L. SatoDirector
NA
Nancy A. ThornberryDirector
PS
Peter S. KleinDirector
MT
Marc Tessier-LavigneDirector
JT
Jay T. FlatleyDirector
DP
David P. SchenkeinDirector
EH
Erik HarrisDirector
SE
Steve E. KrognesDirector
JC
Jennifer CookDirector
RW
Ryan WattsExecutive Officer, Director
AO
Alexander O. SchuthExecutive Officer

Investors · 5

ARCH Venture PartnersChicago · $50K – $250M
EcoR1 CapitalSan Francisco
F-Prime Capital PartnersCambridge · $3M – $10M
Foresite CapitalLarkspur
GV (Google Ventures)reportedMountain View · $250K – $50Mvia David Schenkein · board

Reported raises · per SEC filings

Form D private placements
▶$499.7MraisedMar 2024 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Carole HoExecutive Officer
  • Vicki L. SatoDirector
  • Nancy A. ThornberryDirector
  • Peter S. KleinDirector
  • Marc Tessier-LavigneDirector
  • Jay T. FlatleyDirector
  • David P. SchenkeinDirector
  • Erik HarrisDirector
  • Steve E. KrognesDirector
  • Jennifer CookDirector
  • Ryan WattsExecutive Officer, Director
  • Alexander O. SchuthExecutive Officer
Offering amount
$499.7M
Amount sold
$499.7M
First sale
Feb 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news